September 24, 2018

For many biopharmaceutical companies, the future of drug development lives in the real world

By Greg Reh, Vice Chairman, US and Global Life Sciences Leader, Deloitte LLP

Many biopharmaceutical companies are putting greater emphasis on real-world evidence (RWE) to address regulatory requirements, drive the development of new therapies, and support value-based contracts, according to the results of our second annual RWE benchmarking survey.

These results, combined with examples of how the industry is starting to use RWE, help to reinforce the value of RWE and real-world data (RWD) in the delivery of more personalized, value-driven medicine.

One area in which we are seeing a lot of momentum is in clinical trials. Of the 1,800 clinical trials worldwide that involve RWE or RWD, half of them began within the last three years, and 300 were initiated in 2017, according to a recent Reuters analysis of the National Institutes of Health’s website. Historically, biopharma firms have relied primarily on randomized controlled trials (RCTs) to develop and test new therapies. While RCTs remain a critical component in this process, RWE sometimes offers deeper insight into how a drug or a class of drugs actually performs in the real world.

Read more from Deloitte’s weekly series that explores breaking news and developments in the US health care industry, examines key issues facing life sciences and health care companies, and provides updates and insights on policy, regulatory, and legislative changes.

Greg Reh

DTTL Global Life Sciences Sector Leader